Ignite Creation Date:
2025-12-25 @ 1:19 AM
Ignite Modification Date:
2026-02-22 @ 7:24 AM
Study NCT ID:
NCT02018393
Status:
UNKNOWN
Last Update Posted:
2013-12-23
First Post:
2013-12-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Case-control Pilot Study of the Immune Modulating Effect of FEIBA on Patients With Haemophilia A and Inhibitors
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'CROSS_SECTIONAL', 'observationalModel': 'CASE_CONTROL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 20}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2014-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2013-12', 'completionDateStruct': {'date': '2014-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2013-12-20', 'studyFirstSubmitDate': '2013-12-17', 'studyFirstSubmitQcDate': '2013-12-20', 'lastUpdatePostDateStruct': {'date': '2013-12-23', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2013-12-23', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2014-06', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Measurement of plasma levels of anti-FVIII antibodies (neutralising and non-neutralising)', 'timeFrame': 'At inclusion'}], 'secondaryOutcomes': [{'measure': 'Measurement of the serum levels of inflammatory cytokines', 'timeFrame': 'At inclusion'}]}, 'conditionsModule': {'keywords': ['FEIBA®'], 'conditions': ['Severe Haemophilia A With Inhibitors']}, 'descriptionModule': {'briefSummary': 'This study aims to evaluate the immunomodulatory effect of FEIBA® in patients with severe haemophilia A and inhibitors.', 'detailedDescription': 'This is an observational, multicentric, case-control and one-single-visit study of patients with severe haemophilia A and inhibitors against FVIII in therapy with FEIBA®.\n\nTwo subject groups will be included: Group 1 (cases) will be composed of patients with severe haemophilia A and inhibitors in prophylaxis with FEIBA®; Group 2 (controls) will be composed of patients with severe haemophilia A and inhibitors on-demand treatment with FEIBA®.'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Patients with severe haemophilia A and inhibitors treated with FEIBA® (on demand or prophylaxis) for the control of bleedings.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. The subject has signed and dated the Informed Consent form for participation in this study.\n2. Age ≥ 18 years old.\n3. Patient with severe haemophilia A (FVIII \\<1%) and high-responding inhibitor (titre \\>5 UB) at some point in their life, currently on therapy with FEIBA® to control bleeding.\n4. Group 1: Patients in prophylaxis with FEIBA®: The patient has been on prophylaxis regimen with FEIBA® for at least 6 months prior to the study visit. Group 2: Patients on-demand regimen with FEIBA®: The patient has been under on-demand treatment with FEIBA® for at 6 months prior to the study visit.\n\nExclusion Criteria:\n\n1. The presence of any inflammatory condition at the time of the study visit or the previous 30 days that, according to the medical criterion, would affect the study objectives.\n2. The patient is under immune tolerance treatment or has been at any time during the 30 days prior to the study visit.\n3. The administration of any anti-inflammatory or immunosuppressive drug 15 days before the study visit.\n4. Levels of CD4 \\<200/l regardless of the HIV status.\n5. Altered hepatic or renal function defined by the presence of abnormal levels of alanine aminotransferase (ALAT) or serum creatinine, respectively.\n6. Administration of any haemostatic treatment to control bleeding within the 5 days prior to the study visit.'}, 'identificationModule': {'nctId': 'NCT02018393', 'briefTitle': 'Case-control Pilot Study of the Immune Modulating Effect of FEIBA on Patients With Haemophilia A and Inhibitors', 'organization': {'class': 'OTHER', 'fullName': 'Hospital Universitario La Paz'}, 'officialTitle': 'Case-control Pilot Study of the Immune Modulating Effect of FEIBA on Patients', 'orgStudyIdInfo': {'id': 'PI-1405'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Prophylaxis group', 'description': 'Prophylaxis with FEIBA is defined in this study as the regular infusion of FEIBA for the prevention of bleeding at a dose of ≥50 UF/kg on at least three non-consecutive days a week. Patients must have been on this modality for at least 6 months prior to the study visit'}, {'label': 'On demand group', 'description': 'On-demand Treatment is defined as the administration of FEIBA only to control bleeding. Patients must have been on this modality for at least 6 months prior to the study visit.'}]}, 'contactsLocationsModule': {'locations': [{'zip': '28046', 'city': 'Madrid', 'country': 'Spain', 'facility': 'University Hospital La Paz', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}], 'centralContacts': [{'name': 'Ihosvany Fernandez-Bello, Pharmacist', 'role': 'CONTACT', 'email': 'ihosvanyf@yahoo.es', 'phone': '+34669089737'}], 'overallOfficials': [{'name': 'Victor Jimenez-Yuste, Medical doctor, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital Universitario La Paz'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Hospital Universitario La Paz', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Medical Degree PhD', 'investigatorFullName': 'Victor Jimenez-Yuste', 'investigatorAffiliation': 'Hospital Universitario La Paz'}}}}